MT2
MT2
Melanotan II activates melanocortin receptors across multiple pathways, and research in human subjects has documented significant effects in both skin pigmentation and sexual function. Phase I human trials demonstrated dose-dependent increases in skin tanning in all participants. Separately, controlled human studies showed statistically significant improvements in erectile function attributed to central MC3R/MC4R activation — the same mechanism that later led to FDA approval of the structural derivative bremelanotide (Vyleesi) for hypoactive sexual desire disorder.
Supplied as research-grade lyophilised peptide. Requires reconstitution with bacteriostatic water prior to use. For research purposes only.
Research Stack Builder
Build Your Research Stack
Curated combinations based on what researchers actually stack — backed by published data, priced to save.
Stack with MT2
Why researchers stack these
- 01Melanin, collagen & antioxidant coverage
- 02Counterbalancing pigmentation pathways
- 03Comprehensive skin research protocol
Full research context
Melanotan II drives eumelanin synthesis via MC1R agonism — the primary mechanism for studying skin tanning and melanocortin pathways. GHK-Cu provides the structural skin quality component: collagen density, extracellular matrix integrity, and wound repair that melanin synthesis alone does not address. Glutathione inhibits tyrosinase and shifts melanin production toward pheomelanin, allowing researchers to study the interplay between agonistic and inhibitory pigmentation pathways simultaneously. NAD+ supports the cellular energy demands of enhanced melanocyte and repair activity.
Recovery & Repair Protocol
The most studied peptide combination for tissue repair, injury recovery & musculoskeletal healing
Why researchers stack these
- 01Non-competing structural repair pathways
- 02BPC-157 angiogenesis + TB-500 satellite cell activation
- 03GHK-Cu adds the extracellular matrix layer both lack
Full research context
BPC-157 and TB-500 are the two most frequently co-researched repair peptides in published literature, acting through complementary mechanisms — BPC-157 via nitric oxide pathways and angiogenesis, TB-500 via actin-sequestering and satellite cell activation. GHK-Cu rounds out the stack by supporting collagen synthesis and the extracellular matrix that both compounds do not directly address, while reducing the oxidative load that slows tissue recovery.
Metabolic & Body Recomposition
Most popular Peptide Pal stack — two non-competing fat loss axes with skin integrity support
Why researchers stack these
- 01GLP-1 triple agonism + GH axis — two distinct fat loss pathways
- 02Skin integrity preserved throughout recomposition
- 03Most purchased together on Peptide Pal
Full research context
Retatrutide and Tesamorelin address body composition through two non-competing mechanisms. Retatrutide's triple receptor agonism drives broad metabolic improvement and appetite regulation; Tesamorelin is FDA-approved for visceral adipose reduction through the growth hormone axis — a distinct mechanism. GHK-Cu supports skin integrity during recomposition; rapid fat loss without collagen support produces visible skin laxity that is far harder to address after the fact.
Cognitive Performance Stack
Neuropeptides studied for synergistic cognitive enhancement, focus & stress resilience — no sedation
Why researchers stack these
- 01BDNF stimulation balanced by GABA modulation
- 02Focus without anxiety — three non-competing pathways
- 03NAD+ fuels the neuronal energy demand
Full research context
Semax and Selank are registered pharmaceuticals with distinct mechanisms. Semax drives BDNF upregulation and cortical processing speed; Selank reduces the stress-induced cognitive interference that can blunt that effect, without sedation or dependency. NAD+ provides the cellular energy substrate that enhanced neuronal activity demands — researchers consistently report that this combination delivers balanced cognitive performance that neither compound achieves alone.
Skin & Glow Protocol
Collagen synthesis, antioxidant protection & melanin research in one comprehensive skin stack
Why researchers stack these
- 01Collagen, antioxidant & pigmentation — three skin pillars
- 02Tyrosinase inhibition counterbalances MC1R agonism for pathway research
- 03Structural integrity maintained alongside brightening
Full research context
GHK-Cu stimulates collagen synthesis and modulates over 4,000 genes involved in skin repair and inflammatory control — addressing the structural layer. Glutathione reduces oxidative stress and inhibits tyrosinase, producing measurable skin brightening with 30–35% tissue GSH increases confirmed in human RCTs. MT2 drives eumelanin synthesis via MC1R agonism, and researchers frequently combine it with Glutathione to study the interplay between melanocortin-driven pigmentation and tyrosinase inhibition simultaneously. Together these three represent the most comprehensive skin research protocol available.
Cellular Longevity Protocol
Three compounds that decline together with age — combined restoration for mitochondrial & cellular health
Why researchers stack these
- 01All three decline together with age — parallel restoration
- 02Mitochondrial energy, AMPK signalling & antioxidant protection
- 03Most complete cellular longevity protocol available
Full research context
NAD+, MOTS-c, and glutathione all decline measurably with age through parallel but distinct pathways. NAD+ restores sirtuin and PARP function essential for mitochondrial biogenesis and DNA repair — declining up to 50% by age 60. MOTS-c is the mitochondria-derived peptide that activates AMPK signalling and declines alongside NAD+; their combined restoration is the most researched longevity intervention. Glutathione provides the antioxidant protection that prevents cellular damage during the heightened metabolic activity that NAD+ and MOTS-c restoration drives — completing what researchers describe as the foundational cellular longevity triad.
Research & Studies
Peer-reviewed research supporting MT2
Phase I Human Trial: Melanotan II Produces Dose-Dependent Skin Tanning in Healthy Volunteers
In the first human clinical evaluation of Melanotan II, researchers administered escalating subcutaneous doses to volunteers with Fitzpatrick skin types I and II. All participants showed significant, objectively measured increases in skin pigmentation via colorimetry within five days, confirming MC1R-mediated eumelanin synthesis in vivo. Pigmentation occurred in both sun-exposed and sun-protected areas, demonstrating a systemic melanogenic effect — alongside identification of the spontaneous erection side effect that prompted subsequent investigation of melanocortin agonists for sexual dysfunction, ultimately leading to FDA-approved bremelanotide (Vyleesi).
Melanotan II Produces Erections in Men with Psychogenic Erectile Dysfunction: Controlled Human Trial
A double-blind, placebo-controlled crossover trial in men with psychogenic erectile dysfunction demonstrated that subcutaneous Melanotan II produced statistically significant increases in the rate and rigidity of erections compared to placebo, with 17 of 20 participants responding to the active compound. Erectile events occurred without requiring visual sexual stimulation, confirming central melanocortin pathway activation as the mechanism. The study provided definitive human proof of concept that MC3R and MC4R agonism drives erectile function independently of peripheral vasodilatory mechanisms, supporting the subsequent development of melanocortin-based ED treatments.